Skip to content
Delayed ~15 min

TLSI TRISALUS LF SC CM A

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: Tue 10 Nov 2026 · before market open

What 9 analyst firms say about TRISALUS LF SC CM A: their latest ratings, price targets and how far the stock is from them. How it works

3.25 USD−0.28 (−7.93%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+234.1%to the avg target 10.86 USD+7.61 USD
Buy 5 · Hold 1 · Sell 0

6 rated views · 9 analyst/firm records · 9 firms

Latest report23 Sep 2026avg report date 3 Sep
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
  • Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 8 reports on TLSI from 7 analyst firms in the last 90 days (9 firms in the past year).

Comparing each firm's latest target with its previous one: 1 left it unchanged and 5 have their first observed target in the past year.

No firm's latest available rating differs from its previous one.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Canaccord GenuityWilliam J PlovanicBuy13 Aug 20267.00 USD
GuggenheimUnnamed analyst—23 Sep 202612.00 USD
H.C. WainwrightSwayampakula RamakanthBuy23 Sep 202612.00 USD
JonestradingJustin WalshBuy15 Sep 202611.00 USD
Lake Street Capital MarketsFrank TakkinenBuy3 Aug 20268.00 USD
Maxim GroupJason MccarthyBuy14 Aug 202614.00 USD
StifelUnnamed analyst—23 Sep 202612.00 USD
Weiss RatingsUnnamed analyst—7 Aug 2026—
Data feed RESEARCHResearch TeamHold10 Sep 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 03:26 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.